CASI Pharmaceuticals, Inc. — Investor Relations & Filings
CASI Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics for organ transplantation and autoimmune diseases. The company's lead program is centered on CID-103, an investigational anti-CD38 monoclonal antibody. This therapy is being developed to address antibody-mediated rejection (AMR) in organ transplant recipients, a significant unmet medical need with no currently approved treatments. The mechanism of CID-103 targets B memory cells, plasmablasts, and persistent plasma cells that can contribute to organ rejection. The company is also exploring the potential of this anti-CD38 approach for treating various autoimmune diseases, such as immune thrombocytopenia (ITP).
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 20-F | 2026-05-15 | English | |
| 6-K - CASI Pharmaceuticals, Inc. (0001962738) (Filer) | 2026-04-20 | English | |
| 6-K - CASI Pharmaceuticals, Inc. (0001962738) (Filer) | 2026-04-15 | English | |
| 3 - CASI Pharmaceuticals, Inc. (0001962738) (Issuer) | 2026-03-27 | English | |
| 3 - CASI Pharmaceuticals, Inc. (0001962738) (Issuer) | 2026-03-25 | English | |
| SCHEDULE 13D/A - CASI Pharmaceuticals, Inc. (0001962738) (Subject) | 2026-03-23 | English |
Browse filings by year
4 yearsMarket data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Abliva
Biopharmaceutical company developing medicines for primary …
|
ABLI | SE | Manufacturing |
|
AB Science
Researches and develops protein kinase inhibitors for human…
|
AB | FR | Manufacturing |
|
ABVC BIOPHARMA, INC.
Develops botanical drugs and medical devices for oncology, …
|
ABVC | US | Manufacturing |
|
ACADIA PHARMACEUTICALS INC
Biopharmaceutical company developing medicines for CNS diso…
|
ACAD | US | Manufacturing |
|
Access Bio, Inc.
Develops and manufactures in vitro diagnostic solutions for…
|
950130 | IN | Manufacturing |
|
Accretion Nutraveda Limited
Develops and manufactures pharmaceutical, nutraceutical, an…
|
544694 | IN | Manufacturing |
|
Accretion Pharmaceuticals Limited
Develops and manufactures therapeutic formulations across d…
|
ACCPL | IN | Manufacturing |
|
Acerus Pharmaceuticals Corporation
Specialty pharmaceutical company focused on developing and …
|
ASPCF | CA | Manufacturing |
|
ACHIEVE LIFE SCIENCES, INC.
A late-stage pharmaceutical company developing a treatment …
|
ACHV | US | Manufacturing |
|
Achyut Healthcare Limited
Procures, trades, and manufactures pharmaceutical APIs and …
|
543499 | IN | Manufacturing |
CASI Pharmaceuticals, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34962/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34962 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34962 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34962 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34962}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for CASI Pharmaceuticals, Inc. (id: 34962)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.